Fresenius Medical Care generated Q4 2025 revenue of 5070000000, stable year over year, while operating income more than doubled to 594000000, resulting in an 11.7% operating margin. Net income attributable to shareholders rose to 327000000, reflecting strong profitability gains.

Fresenius Medical Care posted Q4 2024 revenue of €5.09 billion, reflecting a 2% year-over-year increase. Operating income fell 39% to €259 million due to portfolio optimization impacts, while net income dropped 64% to €67 million. The Care Enablement segment drove growth, increasing revenue by 11%, while Care Delivery revenue declined by 1% due to divestitures. Free cash flow improved by 25% to €599 million, supporting deleveraging efforts.